Atypical Hypersensitivity Reaction to Botulinum Toxin Injection

Authors

DOI:

https://doi.org/10.48208/HeadacheMed.2023.21

Keywords:

Botox, Anaphylaxis, Drug-related side effects and adverse reactions, Chronic headache

Abstract

Botulinum toxin type A (BTA) injection, marketed as BOTOX, is commonly used as a treatment for a variety of clinical indications and is widely viewed as safe, effective and largely devoid of serious side effects. Anaphylactic reactions to BTA are typically unheard of in the scientific literature. BOTOX is approved by the Food and Drug Administration for the treatment of cervical dystonia and prophylaxis for chronic migraines. This case report documents a unique instance of allergic reaction to BTA in a 29-year-old woman with cervicogenic headache and cervical dystonia who reported immediate flushing, light-headedness and nausea after receiving BTA injections.     

Downloads

Download data is not yet available.

References

Sjaastad O, Saunte C, Hovdahl H, Breivik H and Grønbâk E. “Cervicogenic” Headache. An Hypothesis. Cephalalgia 2016; 3(4): 249-256 Doi:10.1046/j.1468-2982.1983.0304249.x DOI: https://doi.org/10.1046/j.1468-2982.1983.0304249.x

Moore C, Diaz D and Kane A. Physical Therapy Management of Adults with Mild Traumatic Brain Injury. Seminars in Speech and Language 2019; 40(01): 036-047 Doi:10.1055/s-0038-1676652 DOI: https://doi.org/10.1055/s-0038-1676652

Wu B, Yue L, Sun F, Gao S, Liang B and Tao T. The Feasibility and Efficacy of Ultrasound-Guided C2 Nerve Root Coblation for Cervicogenic Headache. Pain Medicine 2019; 20(6): 1219-1226 Doi:10.1093/pm/pny227 DOI: https://doi.org/10.1093/pm/pny227

Moye LS, Tipton AF, Dripps I, Sheets Z, Crombie A, Violin JD and Pradhan AA. Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology 2019; 148(77-86 Doi:10.1016/j.neuropharm.2018.12.017 DOI: https://doi.org/10.1016/j.neuropharm.2018.12.017

Mares C, Dagher JH and Harissi-Dagher M. Narrative Review of the Pathophysiology of Headaches and Photosensitivity in Mild Traumatic Brain Injury and Concussion. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 2018; 46(1): 14-22 Doi:10.1017/cjn.2018.361 DOI: https://doi.org/10.1017/cjn.2018.361

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, . . . Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30(7): 804-814 Doi:10.1177/0333102410364677 DOI: https://doi.org/10.1177/0333102410364677

Kumar R. Therapeutic use of botulinum toxin in pain treatment. Neuronal Signaling 2018; 2(3): Doi:10.1042/ns20180058 DOI: https://doi.org/10.1042/NS20180058

Wissel J, Müller J, Dressnandt J, Heinen F, Naumann M, Topka H and Poewe W. Management of Spasticity Associated Pain with Botulinum Toxin A. Journal of Pain and Symptom Management 2000; 20(1): 44-49 Doi:10.1016/s0885-3924(00)00146-9 DOI: https://doi.org/10.1016/S0885-3924(00)00146-9

Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA and Calne DB. Treatment of spasticity with botulinum toxin: A double-blind study. Annals of Neurology 1990; 28(4): 512-515 Doi:10.1002/ana.410280407 DOI: https://doi.org/10.1002/ana.410280407

Tsui JC, Jon Stoessl A, Eisen A, Calne S and Calne D. Double-Blind Study of Botulinum Toxin in Spasmodic Torticollis. The Lancet 1986; 328(8501): 245-247 Doi:10.1016/s0140-6736(86)92070-2 DOI: https://doi.org/10.1016/S0140-6736(86)92070-2

Matak, Bölcskei, Bach R and Helyes. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins 2019; 11(8): Doi:10.3390/toxins11080459 DOI: https://doi.org/10.3390/toxins11080459

Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, . . . Decker WW. Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Journal of Allergy and Clinical Immunology 2006; 117(2): 391-397 Doi:10.1016/j.jaci.2005.12.1303 DOI: https://doi.org/10.1016/j.jaci.2005.12.1303

Rodrigues FB, Duarte GS, Marques RE, Castelão M, Ferreira J, Sampaio C, . . . Costa J. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2020; 2020(11): Doi:10.1002/14651858.CD003633.pub4 DOI: https://doi.org/10.1002/14651858.CD003633.pub4

Aggarwal A, Kaul V, Kaur G, Banas E, Sampath P and Roy AK. A new facial expression to botox! The American Journal of Emergency Medicine 2014; 32(3): 290.e295-290.e296 Doi:10.1016/j.ajem.2013.10.017 DOI: https://doi.org/10.1016/j.ajem.2013.10.017

Moon IJ, Chang SE and Kim SD. First case of anaphylaxis after botulinum toxin type A injection. Clinical and Experimental Dermatology 2017; 42(7): 760-762 Doi:10.1111/ced.13108 DOI: https://doi.org/10.1111/ced.13108

Careta MF, Delgado L and Patriota R. Report of Allergic Reaction After Application of Botulinum Toxin. Aesthetic Surgery Journal 2015; 35(5): NP102-NP105 Doi:10.1093/asj/sju105 DOI: https://doi.org/10.1093/asj/sju105

Li M, Goldberger BA and Hopkins C. Fatal case of BOTOX-related anaphylaxis? J Forensic Sci 2005; 50(1): 169-172 DOI: https://doi.org/10.1520/JFS2004196

Downloads

Published

2023-06-30

How to Cite

1.
Ghorayeb J, McClellan T, Crozier K. Atypical Hypersensitivity Reaction to Botulinum Toxin Injection. Headache Med [Internet]. 2023 Jun. 30 [cited 2024 May 9];14(2):108-11. Available from: https://headachemedicine.com.br/index.php/hm/article/view/775

Issue

Section

Case Report